Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 10/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.58 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851900 | 0.88 | PIK3CD (0.45) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL30526584 | 0.83 | PIK3CA (0.57) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL184566 | 0.81 | PIK3CD (0.55) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL30526543 | 0.81 | PIK3CD (0.55) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL10233444 | 0.81 | HTR7 (0.46) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL3512062 | 0.80 | PIK3CD (0.41) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL13408569 | 0.80 | PIK3CD (0.40) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL10233535 | 0.79 | ALDH1A1 (0.38) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL13408571 | 0.77 | MEN1 (0.47) | TSHRNPC1RAB9A | |
| SCHEMBL10233497 | 0.76 | PIK3CD (0.40) | PI4KAPI4KBPIK3CAPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| EP-2105435-A1 | HYDRAZONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | PI4KA 2267/4885PI4KB 2759/4885PIK3CA 1743/4885 |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | GCK, KHK, GCKR | PI4KA 2267/4885PI4KB 2759/4885PIK3CA 1743/4885 |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | GCK, GCKR, HK1 | PI4KA 1521/4885PI4KB 2017/4885PIK3CA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.